Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-05-23

Clinical Trial Update: Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the efficacy of oral vismodegib across basal cell carcinoma subtypes completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vismodegib (Vismodegib)

Snippet

Sponsor: Mayo Clinic | Conditions: Basal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-05-23